PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT04493151: Imipenem/Cilastatin/Relebactam PK in ECMO
Official title: Pharmacokinetics of Imipenem/Cilastatin/Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
Conditions: Sepsis
Summary: Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and re-infused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum antibiotic, imipenem-cilastatin-relebactam, in critically ill patients receiving ECMO.
Interventions:
description: After receipt of imipenem-cilastatin-relebactam, ten blood samples will be collected to determine the pharmacokinetics of imipenem and relebactam.
name: Imipenem, Cilastatin and Relebactam
other_name: Recarbrio
type: Drug
Study arms:
design_group_description: Participants will receive a four to six doses of intravenous imipenem-cilastatin-relebactam as per current prescribing information based on estimated creatinine clearance.
design_group_title: Imipenem-Cilastatin-Relebactam
design_group_type: Experimental
Sponsor: Hartford Hospital
Collaborators: Merck Sharp & Dohme Corp.
Drug name mappings:
name: 西司他丁/亚胺培南/瑞来巴坦
lang: CN
name: Cilastatin Sodium/Imipenem/Relebactam
lang: EN
name: レレバクタム水和物/イミペネム水和物/シラスタチンナトリウム
lang: JP
Clinical trial NCT01522378: Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging
Official title: Cardiac Resynchronization and MIBG Imaging
Conditions: Congestive Heart Failure
Summary: Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
Interventions:
description: 10 millicurie (mCi) (370 MBq)
name: 123 iodine metaiodobenzylguanidine
other_name: AdreView
type: Drug
Study arms:
design_group_description: Subjects will be imaged with 123 iodine metaiodobenzylguanidine.
design_group_title: Biv-ICD
design_group_type: Experimental
Sponsor: Mayo Clinic
Collaborators: GE Healthcare Holdings, Inc.
Drug name mappings:
name: 碘[123I]苄胍
lang: CN
name: Iobenguane I-123
lang: EN
name: 3-ヨードベンジルグアニジン（123I）
lang: JP
Clinical trial NCT04689048: Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
Official title: Characterization of Large Brain Metastases With 18F-Fluciclovine PET/CT Treated With Staged Stereotactic Radiosurgery
Conditions: Brain Metastases, Adult
Brain Metastases
Brain Cancer
Summary: The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In addition, this study will look at the changes of the treated brain metastases using this imaging agent over time.
Interventions:
description: Patients will receive a standard 5 millicuries dose of 18F-fluciclovine intravenously as a bolus injection. They will be required to fast for at least four hours prior to 18F-fluciclovine injection. Patients will be positioned for PET/CT brain imaging and will be injected with 18F-fluciclovine immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
name: 18F fluciclovine
other_name: Axumin
type: Drug
Study arms:
design_group_description: In total, three 18F-fluciclovine PET/CT brain scans (pre-, interim-, and post-treatment) will be performed according to the study calendar. Generic name is Axumin and will be administered as an intravenous bolus. May administer diluted or undiluted. The maximum volume of undiluted 18F-fluciclovine is 5 mL. After administration, flush with normal saline to ensure full delivery of the dose.
design_group_title: PET/CT, MRI
design_group_type: Other
Sponsor: Baptist Health South Florida, Inc.
Collaborators: Blue Earth Diagnostics Ltd.
Drug name mappings:
name: [18F]氟氨基丁酸
lang: CN
name: Fluciclovine 18F
lang: EN
name: フルシクロビン（18F）
lang: JP
Clinical trial NCT03403595: 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Official title: Safety and Dosimetry of 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer
Conditions: Metastatic Castration-resistant Prostate Cancer
Summary: This is an open-label, non-controlled, non-randomized study to assess the safety and measure image-based absorbed dose of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) who will undergo radioliagnd therapy using 177Lu-EB-PSMA-617. All patients underwent whole-body 68Ga-PSMA PET/CT for selection and accepted intravenous injection with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617 within one week, then monitored at 2, 24, 72, 120 and 168 h after 177Lu-EB-PSMA617 administration with serial whole body planar and SPECT/CT imaging.
Interventions:
description: accepted intravenous injection of 177Lu-EB-PSMA-617 and monitored at 2, 24, 72, 120 and 168 hours post-injection.
name: 177Lu-EB-PSMA-617
type: Drug
Study arms:
design_group_description: All patients were intravenous injected with single dose 0.80-1.1 GBq (21.5-30 mCi) of 177Lu-EB-PSMA-617, then monitored at 2, 24, 72, 120 and 168 hours post-injection.
design_group_title: 177Lu-EB-PSMA-617 dosimetry calculation
design_group_type: Experimental
Sponsor: Peking Union Medical College Hospital
Collaborators: National Institute For Biomedical Imaging And Bioengineering (Nibib)
Drug name mappings:
name: 177Lu-EB-PSMA-617(National Institute For Biomedical Imaging And Bioengineering (Nibib))
lang: EN
Clinical trial NCT02837263: PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
Official title: Pembrolizumab in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer
Conditions: Colorectal Cancer
Colorectal Adenocarcinoma
Stage IVA Colorectal Cancer
Stage IVB Colorectal Cancer
Metastatic Carcinoma in the Liver
Summary: The purpose of this research study is:
* To find out how safe the study drug, pembrolizumab, is when combined with stereotactic body radiotherapy (SBRT) to the liver.
* To see how well subjects can tolerate treatment with pembrolizumab and SBRT.
* To find out how often colorectal cancer comes back 1 year after surgically removing all known disease and being treated with SBRT and pembrolizumab.
Interventions:
description: SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.<br/>SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning.
name: Stereotactic body radiotherapy (SBRT)
other_name: Stereotactic Body Radiation Therapy
type: Radiation
description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
name: Pembrolizumab
other_name: Keytruda
Pembro
type: Drug
Study arms:
design_group_description: Subjects will receive stereotactic body radiotherapy (SBRT) within 4 weeks of enrollment. Following SBRT, subjects will receive one cycle of pre-operative pembrolizumab given as an IV over approximately 30 minutes. Surgical management to remove all known sites of metastatic disease should occur 2 weeks post pembrolizumab treatment. Approximately 4-8 weeks after surgery subjects will being the second phase of pembrolizumab treatment. They will receive this treatment every 3 weeks (cycle) for 8 more cycles after surgery. Prior to the 5th cycle of pembrolizumab subjects will also have tumor imaging (CT or MRI).
design_group_title: SBRT + Pembrolizumab
design_group_type: Experimental
Sponsor: University of Wisconsin-Madison
Collaborators: Merck Sharp & Dohme Corp.
Drug name mappings:
name: 帕博利珠单抗
lang: CN
name: Pembrolizumab
lang: EN
name: ペムブロリズマブ（遺伝子組換え）
lang: JP
Clinical trial NCT02115347: Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)
Official title: A Phase 1, Non-randomized, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Hepatic Impairment and the Healthy Subjects With Normal Hepatic Function
Conditions: Type 2 Diabetes Mellitus
Hepatic Impairment
Summary: This is a study to assess the pharmacokinetics and safety of ertugliflozin (MK-8835, PF-04971729) in participants with hepatic impairment versus healthy participants. In Part 1 of the study, participants with moderate hepatic impairment (Child-Pugh score 7-9) and matched healthy participants will be enrolled; depending on results in Part 1, Part 2 may be conducted and will enroll participants with mild hepatic impairment (Child-Pugh score 5-6).
Interventions:
description: Tablet
name: Ertugliflozin 15 mg
type: Drug
Study arms:
design_group_description: Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
design_group_title: Ertugliflozin 15 mg - Moderate Hepatic Impairment
design_group_type: Experimental
design_group_description: Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
design_group_title: Ertugliflozin 15 mg - Healthy Participants
design_group_type: Other
design_group_description: Participants receive a single 15 mg oral dose (tablet) of ertugliflozin
design_group_title: Ertugliflozin 15 mg - Mild Hepatic Impairment
design_group_type: Experimental
Sponsor: Merck Sharp & Dohme Corp.
Collaborators: Pfizer Inc.
Drug name mappings:
name: 艾托格列净
lang: CN
name: Ertugliflozin pidolate
lang: EN
Clinical trial NCT01768338: Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma
Official title: A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma
Conditions: Non-Hodgkin's Lymphoma
Summary: The purpose of this study is to test the safety of rhIL-18 combined with ofatumumab to see what effects (good and bad) it has on subjects and their non-Hodgkin's lymphoma.
Interventions:
description: Ofatumumab with escalating doses of SB-485232
name: Ofatumumab combined with SB-485232
type: Drug
Study arms:
design_group_description: Otatumumab: 1000 mg IV for 4 weeks. SB-485232: escalating doses (3 ug/kg up to 30 ug/kg) for 8 weeks.
design_group_title: Ofatumumab combined with SB-485232
design_group_type: Experimental
Sponsor: Indiana University
Collaborators: Novartis AG
Drug name mappings:
name: Iboctadekin
lang: EN
name: 奥法妥木单抗
lang: CN
name: Ofatumumab
lang: EN
name: オファツムマブ（遺伝子組換え）
lang: JP
Clinical trial NCT03798314: Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
Official title: Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Conditions: Recurrent Nervous System Lymphoma
Recurrent Primary Vitreoretinal DLBCL
Refractory Nervous System Lymphoma
Refractory Primary Vitreoretinal DLBCL
Summary: This phase I trials studies side effects and best dose of pomalidomide when given together with nivolumab in treating patients with primary central nervous system diffuse large B cell lymphoma or primary vitreoretinal diffuse large B cell lymphoma that has come back or that has not responded to treatment. Immunotherapy with monoclonal antibodies, such as pomalidomide and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Interventions:
description: Given IV
name: Nivolumab
other_name: BMS-936558
MDX-1106
NIVO
ONO-4538
Opdivo
type: Biological
description: Given PO
name: Pomalidomide
other_name: 4-Aminothalidomide
Actimid
CC-4047
Imnovid
Pomalyst
type: Drug
Study arms:
design_group_description: Patients receive nivolumab IV over 30 minutes on day 1 and pomalidomide PO on days 1-14. Treatment repeats every 4 weeks until disease progression or unacceptable toxicity.
design_group_title: Treatment (nivolumab and pomalidomide)
design_group_type: Experimental
Sponsor: Mayo Clinic
Collaborators: National Cancer Institute
Drug name mappings:
name: 纳武利尤单抗
lang: CN
name: Nivolumab
lang: EN
name: ニボルマブ（遺伝子組換え）
lang: JP
name: 泊马度胺
lang: CN
name: Pomalidomide
lang: EN
name: ポマリドミド
lang: JP
Clinical trial NCT03469583: Drug Drug Interaction Study for EYP001 With Entecavir
Official title: Study of the Drug Interaction of EYP001a With Entecavir in Healthy Subjects
Conditions: Hepatitis B, Chronic
Summary: This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of EYP100a combined with ETV in healthy men and women dosed in the morning under fasted conditions.
Interventions:
description: EYP001 self administered capsules, morning, with non carbonated water
name: EYP001
other_name: EYP001a
type: Drug
description: Entecavir self administered tablets, morning, with non carbonated water
name: Entecavir 1 MG
other_name: ETV
type: Drug
Study arms:
design_group_description: EYP001 capsules by mouth
design_group_title: EYP001 dose1
design_group_type: Experimental
design_group_description: 2 tablets of 0.5mg, by mouth
design_group_title: Entecavir 1mg
design_group_type: Active Comparator
design_group_description: EYP001 capsules and 2 tablets of Entecavir 0.5mg by mouth
design_group_title: EYP001 dose 1 + Entecavir 1mg
design_group_type: Experimental
Sponsor: ENYO Pharma SA
Collaborators: CPR Pharma Services Pty Ltd.
Drug name mappings:
name: 恩替卡韦
lang: CN
name: Entecavir
lang: EN
name: エンテカビル水和物
lang: JP
name: Vonafexor
lang: EN
Clinical trial NCT05507827: Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
Official title: Phase I Trial Evaluating the Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-Cell Acute Lymphoblastic Leukemia (ALL)
Conditions: Lymphoid Leukemia
Summary: To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.
Interventions:
description: CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration
name: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
type: Drug
description: Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells
name: Treg CD34+HSPC (Orca-T)
type: Drug
Study arms:
design_group_description: Bayesian dose escalation design for the dosing of the donor CD19/CD22-CAR T cells
design_group_title: Dose escalation
design_group_type: Experimental
Sponsor: Stanford University
Collaborators: American Society of Hematology
National Marrow Donor Program
Drug name mappings:
name: CD19/CD22 CAR T cells (Orca Biosystems)
lang: EN
name: Orca-T (Orca Bio)
lang: EN
Clinical trial NCT01590823: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
Official title: Phase 1 Study of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients
Conditions: Blood Coagulation Disorders
Summary: Patients with end stage renal disease carry a high risk for atrial fibrillation (AF) and require oral anticoagulant therapy for prevention of stroke. Often, the oral anticoagulant, warfarin sodium, is prescribed. Managing dialysis patients on warfarin can be fraught will difficulties given the multitude of drug and food interactions, need for frequent coagulation monitoring and dosage adjustment, and concern that warfarin enhances vascular calcification in dialysis patients. Recently, dabigatran etexilate, a direct oral thrombin inhibitor, has been approved for use in AF patients with normal renal function. Since many drugs are eliminated by the kidneys and removed from the plasma during dialysis, it is important to determine proper drug dosing in hemodialysis patients through evaluating pharmacokinetics.
Interventions:
description: All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
name: Dabigatran Etexilate 110 mg
other_name: Dabigatran Etexilate 110 mg (Pradax)
type: Drug
Study arms:
design_group_description: Single dose of Dabigatran etexilate 110 mg po
design_group_title: Dabigatran etexilate 110 mg
design_group_type: Other
Sponsor: Nova Scotia Health Authority
Collaborators: Capital Health Region
University of Montréal
Dalhousie University
Drug name mappings:
name: 甲磺酸达比加群酯
lang: CN
name: Dabigatran Etexilate Mesylate
lang: EN
name: ダビガトランエテキシラートメタンスルホン酸塩
lang: JP
Clinical trial NCT03820180: A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Official title: A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers
Conditions: Bioequivalence
Summary: Bioequivalence study between two inhaler products of fixed dose combination of fluticasone propionate and salmeterol xinafoate inhalation powder
Interventions:
description: 2 inhalations of Test and Reference product in each study period
name: Test Product
other_name: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
type: Drug
description: 2 inhalations of Test and Reference product in each study period
name: Reference Product
other_name: ADVAIR DISKUS 250/50
type: Drug
Study arms:
design_group_description: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent Pharmaceuticals
design_group_title: Test Product
design_group_type: Experimental
design_group_description: ADVAIR DISKUS® 250/50
design_group_title: Reference Product
design_group_type: Active Comparator
Sponsor: Respirent Pharmaceuticals Co. Ltd.
Collaborators: Becro Ltd.
Drug name mappings:
name: 富马酸二甲酯
lang: CN
name: Dimethyl fumarate
lang: EN
name: フマル酸ジメチル
lang: JP
Clinical trial NCT03347292: Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Official title: A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy
Conditions: Carcinoma, Hepatocellular
Summary: This study will determine if the combination of regorafenib and pembrolizumab is safe and tolerated in patients with advanced liver cancer. In addition, the study will explore the anti-tumor activity of this combination as well as potentially identifying blood and tissue biomarkers associated with disease activity, status or response. The study will also investigate how the drugs behave in your body
Interventions:
description: Regorafenib 80mg/120mg/160mg q.d., 3 weeks on / 1 week off + pembrolizumab 200mg i.v. every 3 weeks
name: Regorafenib(Stivarga, BAY73-4506)
type: Drug
description: 200 mg i.v.(Intravenous(ly)) every 3 weeks (Q3W). This dose will not be escalated or deescalated and the dosing schedule will not be changed
name: Pembrolizumab
type: Drug
Study arms:
design_group_description: The regorafenib starting dose will be 120 mg q.d.(once daily) 3 weeks on / 1 week off in combination with the recommended dose of pembrolizumab (200 mg Q3W). Pembrolizumab dose will not be escalated or de-escalated.
design_group_title: Dose escalation
design_group_type: Experimental
design_group_description: Dose expansion cohorts will continue to be expanded until the sample size of 30-35 patients per cohort is reached.
design_group_title: Dose expansion
design_group_type: Experimental
Sponsor: Bayer AG
Collaborators: Merck Sharp & Dohme Corp.
Drug name mappings:
name: 瑞戈非尼
lang: CN
name: Regorafenib
lang: EN
name: レゴラフェニブ水和物
lang: JP
name: 帕博利珠单抗
lang: CN
name: Pembrolizumab
lang: EN
name: ペムブロリズマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04691817: Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Official title: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Conditions: Lung Cancer, Nonsmall Cell
Summary: This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
Interventions:
description: 1200mg infusion
name: Atezolizumab
other_name: Tecentriq
type: Drug
description: Tocilizumab 6mg/kg or 4mg/kg infusion
name: Tocilizumab
other_name: Actemra, RoActemra, RO4877533
type: Drug
Study arms:
design_group_description: Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg/kg IV (or Tocilizumab 4mg/kg IV) every 21 days
design_group_title: Atezolizumab and Tocilizumab
design_group_type: Experimental
Sponsor: Abramson Cancer Center
Collaborators: Genentech, Inc.
Drug name mappings:
name: 托珠单抗
lang: CN
name: Tocilizumab
lang: EN
name: トシリズマブ（遺伝子組換え）
lang: JP
name: 阿替利珠单抗
lang: CN
name: Atezolizumab
lang: EN
name: アテゾリズマブ（遺伝子組換え）
lang: JP